^
    7d
    A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland (clinicaltrials.gov)
    P=N/A, N=110, Not yet recruiting, Takeda
    New trial • Real-world evidence
    |
    Fruzaqla (fruquintinib)
    7d
    A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    capecitabine • oxaliplatin • Fruzaqla (fruquintinib) • Hetronifly (serplulimab)
    8d
    The Mutational Landscape of Angiosarcoma: Challenges and Opportunities to Design Management Strategies. (PubMed, Curr Mol Med)
    Recent clinical trials (Axi-STS, TAPPAS) demonstrated that single-agent anti-angiogenic inhibitors (axitinib, pazopanib) achieve modest efficacy (median progression-free survival (PFS) 3.0-4.3 months, response rates 5-13%), underscoring angiosarcoma's complex, multipathway-driven pathogenesis. Environmental exposures (vinyl chloride, thorotrast, radiation) drive distinct angiosarcoma subtypes with subtype-specific mutational profiles. We propose that precision-medicine approaches integrating molecular stratification, pathway crosstalk analysis, and biomarker-guided combination therapies represent the rational next steps to overcome therapeutic resistance and improve clinical outcomes in this lethal malignancy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • ENG (Endoglin) • CDH5 (Cadherin 5)
    |
    TP53 mutation • PIK3CA mutation
    |
    pazopanib • axitinib
    8d
    Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. (PubMed, Leukemia)
    Moreover, FTY720 co-treatment resensitized G12D NRAS-mutated M14(R)701 cells to gilteritinib in vivo. Co-treatment inactivated ERK, transcriptionally downregulated SPHK1, and inactivated downstream AKT, p70 S6K and BAD, with inactivation abrogated by constitutive SPHK1 expression. The clinically applicable S1PR modulators fingolimod and mocravimod resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors, supporting potential clinical efficacy.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SPHK1 (Sphingosine Kinase 1)
    |
    NRAS mutation • FLT3-ITD mutation • FLT3 mutation • RAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Xospata (gilteritinib) • fingolimod • mocravimod (KRP-203)
    12d
    Comprehensive characterization of spinal ependymomas in NF2-Schwannomatosis. (PubMed, Acta Neuropathol Commun)
    These results support a role for VEGF signaling and macrophage-mediated microenvironmental changes in edema and cystic growth of NF2-SWN SE. The observed clinical response to AXITINIB in an index patient suggests that new combinations of anti-angiogenic therapies may represent a promising early targeted approach.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
    |
    axitinib
    12d
    A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas (clinicaltrials.gov)
    P3, N=136, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd
    New P3 trial
    |
    Avastin (bevacizumab) • hydroxyurea • SYHA1813
    13d
    Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> May 2027
    Trial completion date
    |
    Lynparza (olaparib) • Recentin (cediranib)
    13d
    Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China. (PubMed, Future Oncol)
    Monotherapy subgroup reported the lowest incidence of TEAEs (74.47%) and grade ≥3 TEAEs (23.94%), while the fruquintinib + chemotherapy subgroup reported the highest incidence (85.52%). Fruquintinib combination therapy demonstrated a satisfactory safety profile within the treatment groups.
    Journal • Real-world evidence
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    Fruzaqla (fruquintinib)
    14d
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    15d
    COFRUQ: Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    15d
    NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P1/2, N=139, Active, not recruiting, Alcon Research | Trial primary completion date: Oct 2027 --> May 2027
    Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    18d
    Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia. (PubMed, J Med Chem)
    In vivo, FYJ-195 induced profound tumor regression (TGI = 125%) in the MV4-11 xenograft model (10 mg/kg) and achieved robust tumor growth suppression (TGI = 68.6%) in the Ba/F3-FLT3-ITD-F691L model (50 mg/kg), where quizartinib was ineffective. Mechanistic studies confirmed that FYJ-195 effectively blocked FLT3 signaling and induced apoptosis without observable toxicity. Collectively, FYJ-195 represents a promising lead candidate for drug-resistant AML.
    Preclinical • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Vanflyta (quizartinib)